bevacizumab (Avastin) -

bevacizumab (Avastin)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Obstetrics and gynaecology
Summary
The SMC has accepted for restricted use within NHS Scotland, bevacizumab for the treatment of adults with persistent, recurrent, or metastatic carcinoma of the cervix. It is restricted for use in combination with cisplatin and paclitaxel, or paclitaxel and topotecan.
UKMi comment
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of bevacizumab, and is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Related links: